tiprankstipranks
Jubilant Pharmova Limited (IN:JUBLPHARMA)
:JUBLPHARMA
India Market
Want to see IN:JUBLPHARMA full AI Analyst Report?

Jubilant Pharmova Limited (JUBLPHARMA) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

JUBLPHARMA Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Jubilant
Pharmova Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JUBLPHARMA Stock 12 Month Forecast

There Are No Analyst Ratings for IN:JUBLPHARMA In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

JUBLPHARMA Financial Forecast

JUBLPHARMA Earnings Forecast

The previous quarter’s earnings for JUBLPHARMA were ₹8.00.
The previous quarter’s earnings for JUBLPHARMA were ₹8.00.

JUBLPHARMA Sales Forecast

The previous quarter’s earnings for JUBLPHARMA were ₹22.90B.
The previous quarter’s earnings for JUBLPHARMA were ₹22.90B.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
ICICI Securities Analyst forecast on IN:JUBLPHARMA
Unknown Analyst
ICICI Securities
Not Ranked
ICICI Securities
₹1,310
Buy
24.04%
Upside
Reiterated
02/08/26
ICICI Securities Reaffirms Their Buy Rating on Jubilant Pharmova Limited (JUBLPHARMA)
Nuvama
₹1,385
Buy
31.14%
Upside
Reiterated
06/27/25
Nuvama Sticks to Their Buy Rating for Jubilant Pharmova Limited (JUBLPHARMA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
ICICI Securities Analyst forecast on IN:JUBLPHARMA
Unknown Analyst
ICICI Securities
Not Ranked
ICICI Securities
₹1,310
Buy
24.04%
Upside
Reiterated
02/08/26
ICICI Securities Reaffirms Their Buy Rating on Jubilant Pharmova Limited (JUBLPHARMA)
Nuvama
₹1,385
Buy
31.14%
Upside
Reiterated
06/27/25
Nuvama Sticks to Their Buy Rating for Jubilant Pharmova Limited (JUBLPHARMA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jubilant Pharmova Limited

3 Months
Success Rate
0/1 ratings generated profit
0%
Average Return
-10.60%
Copying Shrikant Akolkar's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -10.60% per trade.
1 Year
Success Rate
0/1 ratings generated profit
0%
Average Return
-13.90%
Copying Shrikant Akolkar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -13.90% per trade.
2 Years
Success Rate
0/1 ratings generated profit
0%
Average Return
-13.90%
Copying Shrikant Akolkar's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -13.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JUBLPHARMA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
0
1
1
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
1
1
1
0
In the current month, JUBLPHARMA has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. JUBLPHARMA average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

JUBLPHARMA Stock Forecast FAQ

What is IN:JUBLPHARMA’s average 12-month price target, according to analysts?
Currently, no data Available
What is IN:JUBLPHARMA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:JUBLPHARMA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Jubilant Pharmova Limited a Buy, Sell or Hold?
      Currently, no data Available
      What is Jubilant Pharmova Limited’s share price target?
      Currently, no data Available
      What do analysts say about Jubilant Pharmova Limited?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Jubilant Pharmova Limited?
      To buy shares of IN:JUBLPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.